PDI inks one-year sales agreement

Share this article:
Contract sales firm PDI has inked a one-year sales agreement for a cardiology drug with an unnamed “top-10 pharmaceutical company.”

The initiative, expected to bring in $13 million in revenue, will target primary care physicians and cardiologists and was scheduled to begin April 2.

The announcement is viewed as a much-needed boost for PDI, which announced a decision by a “large pharma company” client not to renew a $35 million contract sales engagement with the firm. PDI previously expected that one-year deal to be extended through the end of 2007.

PDI has endured four major contract losses during the past year.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...